Last reviewed · How we verify
NCT04441671
Oral Pyrophosphate Absorption in PXE Disease
Phase 2 trial testing Disodium Pyrophosphate in Pseudoxanthoma Elasticum. Withdrawn.
1 April 2021
Quick facts
| Lead sponsor | Tampere University Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 8 December 2020 |
| Primary completion | 1 April 2021 |
| Estimated completion | 1 April 2021 |
Drugs / interventions tested
- Disodium Pyrophosphate — full drug profile →
Conditions studied
- Pseudoxanthoma Elasticum — all drugs for Pseudoxanthoma Elasticum →
Sponsor
Tampere University Hospital
Who can join
Adults 18 to 80, any sex, with Pseudoxanthoma Elasticum. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Pyrophosphate is an endogenous, non-toxic metabolite inhibiting soft tissue calcification. The aim of our study is to find optimal dosing and safety of oral disodium-PPi (Na2H2PPi). Absorption curves (pharmacokinetics), AUC0-t, Cmax and Tmax for PPi and phosphate will be provided for healthy controls and PXE-patients both fasting and with standard meal intake.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
ABCC6, Pyrophosphate and Ectopic Calcification: Therapeutic Solutions.
Shimada BK, Pomozi V, Zoll J, Kuo S, et al · · 2021 · cited 45× · PMID 33925341 · DOI 10.3390/ijms22094555 -
Therapeutics Development for Pseudoxanthoma Elasticum and Related Ectopic Mineralization Disorders: Update 2020.
Luo H, Li Q, Cao Y, Uitto J. · · 2020 · cited 24× · PMID 33396306 · DOI 10.3390/jcm10010114
Verify or expand the search:
- PubMed search for NCT04441671
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pseudoxanthoma Elasticum
Currently open trials in the same condition.
- NCT05734196 — The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency · Phase 1 · recruiting
- NCT05832580 — The Prevention of Systemic Ectopic Mineralization in Pseudoxanthoma Elasticum · Phase 3 · recruiting
- NCT04868578 — PPI Supplementation to Fight ECtopIc Calcification in PXE · NA · recruiting
- NCT05662085 — Progression Rate of Pseudoxanthoma Elasticum-associated Choroidal and Retinal Degeneration · active not recruiting
Other Tampere University Hospital trials
Trials by the same sponsor.
- NCT07315568 — Couples and Microbial Diversity · not yet recruiting
- NCT07128992 — Need-driven Treatment of the Patients With Type 1 Diabetes · not yet recruiting
- NCT07042139 — No Reduction Compared to Closed Reduction for Distal Radius Fractures in Patients Over 65 or Older · NA · recruiting
- NCT07528833 — Health Effects of Mindfulness Based Stress Reduction Course in Treatment of Back Pain · NA · recruiting
- NCT06711796 — Measurement of Muscle Relaxation of the Hand in From Two Muscles and Two Hand Positions · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04441671 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tampere University Hospital
- Last refreshed: 22 April 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04441671.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing